Bladder cancer is a common form of cancer, which progresses by spreading into surrounding muscle. This advanced stage, called muscleinvasive bladder cancer (MIBC), is associated with poor prognosis due to a lack of effective treatment options.
Currently, treatment is restricted to the surgical removal of cancerous tissue combined with radiotherapy and/or chemotherapy, which are both associated with severe side-effects as they affect both cancerous and noncancerous cells. In addition, determining the appropriate therapeutic regime for bladder cancers is hampered by a lack of accurate imaging technology.
Antibody-drug conjugates (ADCs) or Radiolabelled Immunoconjugates (RICs) use the specificity of antibodies to target only cancerous cells. We are therefore developing a targeted ADC and RIC for MIBC as no products are currently available to meet this need.
The interleukin-5 receptor (IL5-Rα) has been validated as a biomarker of advancing bladder cancer. Therefore, cells expressing IL5-Rα can be targeted by RICs and ADCs for imaging and treatment respectively.
We have developed a monoclonal antibody (mAb), which can be conjugated with either a chemotherapeutic agent or a radioligand. In addition these mAbconjugates have been packaged with additional structural technology for enhanced cellular accumulation in IL5-Rα (CD125)-positive MIBC cells.
These targeted molecular conjugates (ADC & RIC) will deliver the therapeutic agent directly to invasive cancerous cells with exquisite selectivity and can be used for diagnostic purposes to accurately determine the extent of the cancer prior to undertaking a treatment plan.
The technology can be used in cancer therapeutic and diagnostic fields.
The team is seeking partners for licensing and co-development opportunities.
A Monoclonal Antibody-drug conjugate that specifically targets advancing bladder cancer cells.